Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Dec 24;332(24):2081-2090.
doi: 10.1001/jama.2024.22718.

Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury: A Randomized Clinical Trial

Collaborators, Affiliations
Randomized Controlled Trial

Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury: A Randomized Clinical Trial

Abinet M Aklilu et al. JAMA. .

Abstract

Importance: Acute kidney injury (AKI) is a common complication during hospitalization and is associated with adverse outcomes.

Objective: To evaluate whether diagnostic and therapeutic recommendations sent by a kidney action team through the electronic health record improve outcomes among patients hospitalized with AKI compared with usual care.

Design, setting, and participants: Randomized clinical trial conducted at 7 hospitals in 2 health systems: in New Haven, Bridgeport, New London, and Waterbury, Connecticut, and Westerly, Rhode Island; and in Baltimore, Maryland. Hospitalized patients with AKI were randomized between October 29, 2021, and February 8, 2024. Final follow-up occurred February 22, 2024.

Intervention: An alert about AKI was sent to the kidney action team, consisting of a study physician and study pharmacist, which sent personalized recommendations through the electronic health record in 5 major categories (diagnostic testing, volume, potassium, acid base, and medications) within 1 hour of AKI detection. The note was immediately visible to anyone with access to the electronic health record. Randomization to the intervention or usual care occurred after the recommendations were generated, but the note was only delivered to clinicians of patients randomized to the intervention group.

Main outcomes and measures: The primary outcome was a composite outcome consisting of AKI progression to a higher stage of AKI, dialysis, or mortality occurring while the patient remained hospitalized and within 14 days from randomization.

Results: Of the 4003 patients randomized (median age, 72 years [IQR, 61-81 years), 1874 (47%) were female and 931 (23%) were Black patients. The kidney action team made 14 539 recommendations, with a median of 3 (IQR, 2-5) per patient. The primary outcome occurred in 19.8% of the intervention group and in 18.4% in the usual care group (difference, 1.4%, 95% CI, -1.1% to 3.8,% P = .28). Of 6 secondary outcomes, only 1 secondary outcome, rates of recommendation implementation, significantly differed between the 2 groups: 2459 of 7270 recommendations (33.8%) were implemented in the intervention group and 1766 of 7269 undelivered recommendations (24.3%) were implemented in the usual care group within 24 hours (difference, 9.5%; 95% CI, 8.1% to 11.0%).

Conclusions and relevance: Among patients hospitalized with AKI, recommendations from a kidney action team did not significantly reduce the composite outcome of worsening AKI stage, dialysis, or mortality, despite a higher rate of recommendation implementation in the intervention group than in the usual care group.

Trial registration: ClinicalTrials.gov Identifier: NCT04040296.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Menez reported receiving grant support from the National Institutes of Health. Dr Moledina reported serving as a consultant for BioHaven Inc and being a coninventor of a patent and cofounder of Predict AIN LLC. Dr Testani reported receiving grants or personal fees from 3ive labs, Bayer, Bristol Myers Squibb, AstraZeneca, Novartis, Cardionomic, MagentaMed, Reprieve Inc, FIRE1, W. L. Gore, Sanofi, Sequana Medical, Otsuka, Abbott, Merck, Windtree Therapeutics, Lexicon Pharmaceuticals, Precardia, Relypsa, Regeneron, BD, Edwards Lifesciences, and Lilly; having a patent for treatment of diuretic resistance issued to Yale and Corvidia Therapeutics Inc, for methods for measuring renalase issued to Yale, and for treatment of diuretic resistance pending with Reprieve Inc. Dr Parikh reported receiving grants U54DK137331, U01DK114866, U01DK129984, and R01DK093770 from the National Institutes of Health; serving on the scientific advisory boards of Alexion, Bayer, and Otsuka; and being a coinventor of a pending patent and cofounder of Predict AIN, LLC. Dr Wilson reported receiving research funding from Amgen, AstraZeneca, Whoop, and Vifor Pharma and consulting fees from Aura Care and Hekaheart, LLC. No other disclosures were reported.

Figures

Figure.
Figure.. Study Flow of Patients in the KAT-AKI Study
aEligibility was based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria, age older than 18 years, no known end-stage kidney disease, and no hospice flag. A physician and a pharmacist, members of the kidney action team (KAT), received an electronic acute kidney injury (AKI) alert as soon as a patient met KDIGO-creatinine AKI criteria. The KAT members screened the patient’s chart further for eligibility criteria, provided recommendations in 5 major areas of evaluation and management, and the KAT randomized the patients to either the intervention group or the usual care group. Recommendations were only entered into the electronic health record of patients randomized to the intervention group. bA patient could meet multiple exclusion criteria.

References

    1. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365-3370. doi:10.1681/ASN.2004090740 - DOI - PubMed
    1. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442-448. doi:10.1038/ki.2011.379 - DOI - PMC - PubMed
    1. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol. 2010;298(5):F1078-F1094. doi:10.1152/ajprenal.00017.2010 - DOI - PMC - PubMed
    1. Kashani K, Rosner MH, Haase M, et al. . Quality improvement goals for acute kidney injury. Clin J Am Soc Nephrol. 2019;14(6):941-953. doi:10.2215/CJN.01250119 - DOI - PMC - PubMed
    1. Macedo E, Bihorac A, Siew ED, et al. . Quality of care after AKI development in the hospital: consensus from the 22nd Acute Disease Quality Initiative (ADQI) conference. Eur J Intern Med. 2020;80:45-53. doi:10.1016/j.ejim.2020.04.056 - DOI - PMC - PubMed

Publication types

Associated data